Literature DB >> 20032820

Evidence for association of two variants of the nociceptin/orphanin FQ receptor gene OPRL1 with vulnerability to develop opiate addiction in Caucasians.

Judith A Briant1, David A Nielsen, Dmitri Proudnikov, Douglas Londono, Ann Ho, Jurg Ott, Mary Jeanne Kreek.   

Abstract

OBJECTIVES: The OPRL1 gene encodes the nociceptin/orphanin FQ receptor, which plays a role in regulating tolerance and behavioral responses to morphine. However, there is limited information on whether variants of OPRL1 are associated with vulnerability to develop opiate addiction. In this study, we examined five variants of OPRL1 and their role in determining vulnerability to develop opiate addiction.
METHODS: We recruited 447 individuals: 271 former severe heroin addicts and 176 healthy controls. Using a 5'-fluorogenic exonuclease assay, we genotyped individuals at five variants in OPRL1. It was then determined whether there was a significant association of allele, genotype, or haplotype frequency with vulnerability to develop opiate addiction.
RESULTS: When the cohort was stratified by ethnicity, we found that, in Caucasians but not in African-Americans or Hispanics, the allele frequency of rs6090041 and rs6090043 were significantly associated point-wise with opiate addiction (P=0.03 and 0.04, respectively). Of the haplotypes formed by these two variants, one haplotype was found to be associated with protection from developing opiate addiction in both African-Americans (point-wise P=0.04) and Caucasians (point-wise P=0.04), and another haplotype with vulnerability to develop opiate addiction in Caucasians only (P=0.020).
CONCLUSION: This study provides evidence for an association of two variants of the OPRL1 gene, rs6090041 and rs6090043, with vulnerability to develop opiate addiction, suggesting a role for nociceptin/orphanin FQ receptor in the development of opiate addiction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20032820      PMCID: PMC3832186          DOI: 10.1097/YPG.0b013e32833511f6

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  40 in total

1.  Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms.

Authors:  Zhaohui S Qin; Tianhua Niu; Jun S Liu
Journal:  Am J Hum Genet       Date:  2002-11       Impact factor: 11.025

Review 2.  Function and regulation of CREB family transcription factors in the nervous system.

Authors:  Bonnie E Lonze; David D Ginty
Journal:  Neuron       Date:  2002-08-15       Impact factor: 17.173

3.  Efficiency and power in genetic association studies.

Authors:  Paul I W de Bakker; Roman Yelensky; Itsik Pe'er; Stacey B Gabriel; Mark J Daly; David Altshuler
Journal:  Nat Genet       Date:  2005-10-23       Impact factor: 38.330

Review 4.  Alcoholism and neuropeptides: an update.

Authors:  M S Cowen; A J Lawrence
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-04       Impact factor: 4.388

5.  Partial loss of tolerance liability to morphine analgesia in mice lacking the nociceptin receptor gene.

Authors:  H Ueda; T Yamaguchi; S Tokuyama; M Inoue; M Nishi; H Takeshima
Journal:  Neurosci Lett       Date:  1997-11-21       Impact factor: 3.046

6.  Phosphorylation of cellular proteins regulates their binding to the cAMP response element.

Authors:  A Merino; L Buckbinder; F H Mermelstein; D Reinberg
Journal:  J Biol Chem       Date:  1989-12-15       Impact factor: 5.157

7.  Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats.

Authors:  N P Murphy; H T Ly; N T Maidment
Journal:  Neuroscience       Date:  1996-11       Impact factor: 3.590

Review 8.  Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments.

Authors:  Mary Jeanne Kreek; Gavin Bart; Charles Lilly; K Steven LaForge; David A Nielsen
Journal:  Pharmacol Rev       Date:  2005-03       Impact factor: 25.468

9.  The AP-1 transcription factor c-Jun is required for efficient axonal regeneration.

Authors:  Gennadij Raivich; Marion Bohatschek; Clive Da Costa; Osuke Iwata; Matthias Galiano; Maria Hristova; Abdolrahman S Nateri; Milan Makwana; Lluís Riera-Sans; David P Wolfer; Hans-Peter Lipp; Adriano Aguzzi; Erwin F Wagner; Axel Behrens
Journal:  Neuron       Date:  2004-07-08       Impact factor: 17.173

10.  ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization.

Authors:  C Mollereau; M Parmentier; P Mailleux; J L Butour; C Moisand; P Chalon; D Caput; G Vassart; J C Meunier
Journal:  FEBS Lett       Date:  1994-03-14       Impact factor: 4.124

View more
  8 in total

1.  Nociceptin attenuates the escalation of oxycodone self-administration by normalizing CeA-GABA transmission in highly addicted rats.

Authors:  Marsida Kallupi; Lieselot L G Carrette; Jenni Kononoff; Leah C Solberg Woods; Abraham A Palmer; Paul Schweitzer; Olivier George; Giordano de Guglielmo
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-13       Impact factor: 11.205

Review 2.  The genetics of the opioid system and specific drug addictions.

Authors:  Orna Levran; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Hum Genet       Date:  2012-05-01       Impact factor: 4.132

3.  Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.

Authors:  Marsida Kallupi; Giulia Scuppa; Giordano de Guglielmo; Girolamo Calò; Friedbert Weiss; Michael A Statnick; Linda M Rorick-Kehn; Roberto Ciccocioppo
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

4.  Asparagine synthetase deficiency detected by whole exome sequencing causes congenital microcephaly, epileptic encephalopathy and psychomotor delay.

Authors:  Salma Ben-Salem; Joseph G Gleeson; Aisha M Al-Shamsi; Barira Islam; Jozef Hertecant; Bassam R Ali; Lihadh Al-Gazali
Journal:  Metab Brain Dis       Date:  2014-09-17       Impact factor: 3.584

5.  Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders.

Authors:  Brian J O'Roak; Laura Vives; Wenqing Fu; Jarrett D Egertson; Ian B Stanaway; Ian G Phelps; Gemma Carvill; Akash Kumar; Choli Lee; Katy Ankenman; Jeff Munson; Joseph B Hiatt; Emily H Turner; Roie Levy; Diana R O'Day; Niklas Krumm; Bradley P Coe; Beth K Martin; Elhanan Borenstein; Deborah A Nickerson; Heather C Mefford; Dan Doherty; Joshua M Akey; Raphael Bernier; Evan E Eichler; Jay Shendure
Journal:  Science       Date:  2012-11-15       Impact factor: 47.728

Review 6.  Current status of opioid addiction treatment and related preclinical research.

Authors:  M J Kreek; B Reed; E R Butelman
Journal:  Sci Adv       Date:  2019-10-02       Impact factor: 14.136

Review 7.  Epigenetic Modulation of Opioid Receptors by Drugs of Abuse.

Authors:  Ke Zhang Reid; Brendan Matthew Lemezis; Tien-Chi Hou; Rong Chen
Journal:  Int J Mol Sci       Date:  2022-10-05       Impact factor: 6.208

Review 8.  Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.

Authors:  Jamie A Burns; Danielle S Kroll; Dana E Feldman; Christopher Kure Liu; Peter Manza; Corinde E Wiers; Nora D Volkow; Gene-Jack Wang
Journal:  Front Psychiatry       Date:  2019-09-18       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.